ALXO

ALX Oncology Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for cancer patients. Headquartered in Burlingame, California, the company concentrates on discovering and developing therapeutics that block the CD47 immune checkpoint pathway to enable the immune system to attack cancer cells. Its lead product candidate, evorpacept (ALX148), is a next-generation CD47 blocking therapeutic designed to maximize efficacy while minimizing adverse effects associated with CD47 blockade. The company advances evorpacept through multiple clinical trials across various cancer indications, including head and neck squamous cell carcinoma, gastric cancer, and breast cancer, both as a monotherapy and in combination with other anti-cancer agents. ALX Oncology collaborates with leading academic institutions and clinical research organizations to conduct its clinical programs. Founded in 2015, the company completed its initial public offering in July 2020. The firm focuses its research efforts on understanding tumor immune evasion mechanisms and translating these insights into therapeutic interventions. ALX Oncology maintains strategic partnerships to expand the development and potential commercialization of its pipeline candidates. The company operates with a business model centered on advancing its proprietary candidates through clinical development stages while exploring partnership opportunities for late-stage development and commercialization activities in certain markets.